Phase 2 trial

October 10, 2019

Copiktra Receives FDA’s Orphan Drug Status for T-cell Lymphoma Treatment

News

The small molecule inhibitor Copiktra (duvelisib) has been given orphan status by the U.S. Food and Drug Administration (FDA) for the treatment of T-cell lymphoma, the therapy’s developer, Verastem Oncology, ... Read more

January 14, 2019

Burkitt’s Lymphoma/Leukemia Patients Being Recruited for CPI-613 Phase 2 Trial

News

Rafael Pharmaceuticals is currently enrolling patients with relapsed or refractory Burkitt’s lymphoma/leukemia in a Phase 2 trial to assess the potential of its lead candidate CPI-613. The study (NCT03793140) is ... Read more

January 11, 2019

Epizyme Planning to Request FDA’s Accelerated Approval of Tazemetostat for Follicular Lymphoma Patients

News

Epizyme plans to ask the U.S. Food and Drug Administration (FDA) for accelerated approval of tazemetostat as a treatment for people with relapsed or refractory follicular lymphoma with or without EZH2 activating mutations. ... Read more

September 11, 2018

Adcetris-Chemotherapy Combo Improves Survival Rates in Elderly Hodgkin’s Patients, Phase 2 Trial Shows

News

Adding Adcetris (brentuximab vedotin) to standard chemotherapy significantly improves responses and survival rates of elderly patients with newly diagnosed Hodgkin’s lymphoma, a Phase 2 study shows. In the trial, 90% of ... Read more

July 3, 2018

FDA Names CPI-613, Potential Treatment for Burkitt’s Lymphoma, an Orphan Drug

News

The U.S. Food and Drug Administration has again designated Rafael Pharmaceuticals’ lead candidate CPI-613 an orphan drug, this time to further advance it in clinical trials as a potential treatment for Burkitt’s lymphoma. ... Read more

May 22, 2018May 22, 2018

Adcetris-Dacarbazine Combo is Effective in Elderly Hodgkin’s Patients, Study Finds

News

A combination of Adcetris (brentuximab vedotin) and dacarbazine chemotherapy may be a suitable option for frail, elderly patients with classical Hodgkin’s lymphoma who are ineligible for standard treatment, according to data ... Read more

March 14, 2018March 14, 2018

G100-Keytruda Combo Shows Higher Response in Follicular Lymphoma Patients in Phase 2 Trial

News

Data from a Phase 2 clinical trial showed that combining Immune Design‘s experimental immunotherapy G100 with fractioned, low-dose radiation and Keytruda (pembrolizumab) leads to higher response rates in follicular lymphoma patients, the company announced. The randomized ... Read more

February 6, 2018February 6, 2018

Cellectar Enrolls First DLBCL Patient in Phase 2 Trial Testing CLR 131 in Refractory B-cell Cancers

News

Cellectar Biosciences has recruited the first patient with diffuse large B-cell lymphoma (DLBCL) into its Phase 2 clinical trial testing the company’s lead investigational phospholipid-drug conjugate, CLR 131. The trial includes ... Read more

December 8, 2017December 8, 2017

Phase 2 Trial Testing Gazyva Combo Regimens in Relapsed Follicular Lymphoma Now Enrolling Participants

News

Biopharmaceutical company TG Therapeutics and the National Cancer Institute’s SWOG have initiated a Phase 2 trial testing three Gazyva (obinutuzumab) regimens in patients with relapsed or refractory follicular lymphoma. The ... Read more

August 16, 2017August 16, 2017

TGR-1202 and TG-1101 Combo Is Effective Enough Against Lymphoma to Continue Being Tested in Phase 2 Trial

News

A combination of two of TG Therapeutics’ lymphoma treatments proved effective enough to continue enrolling patients in a Phase 2b clinical trial, the company announced. But one of the two failed ... Read more